Profile data is unavailable for this security.
About the company
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
- Revenue in USD (TTM)0.00
- Net income in USD-22.06m
- Incorporated2021
- Employees13.00
- LocationCingulate Inc1901 W. 47Th PlaceKANSAS CITY 66205United StatesUSA
- Phone+1 (913) 942-2300
- Fax+1 (302) 636-5454
- Websitehttps://www.cingulate.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impact Biomedical Inc | 25.00k | -44.19m | 47.77m | 2.00 | -- | -- | -- | 1,910.80 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| Clene Inc | 214.00k | -30.50m | 47.96m | 75.00 | -- | -- | -- | 224.10 | -3.33 | -3.33 | 0.0231 | -1.21 | 0.0079 | 0.4021 | 0.475 | 2,853.33 | -113.20 | -55.54 | -280.47 | -72.66 | 82.24 | 76.19 | -14,250.47 | -6,165.10 | 1.52 | -8.71 | 3.64 | -- | -47.71 | -- | 20.41 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 48.49m | 21.00 | -- | 6.85 | -- | 9.22 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 48.56m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| Lipocine Inc | 4.32m | -5.48m | 48.91m | 16.00 | -- | 3.38 | -- | 11.32 | -1.04 | -1.04 | 0.7933 | 2.61 | 0.2351 | -- | 41.82 | 270,168.10 | -29.78 | -30.54 | -32.92 | -34.86 | -- | -- | -126.66 | -194.90 | -- | -- | 0.00 | -- | 492.80 | 132.45 | 100.05 | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 49.23m | 75.00 | -- | 0.3827 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 50.43m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -28.42m | 50.67m | -- | -- | 6.33 | -- | -- | -1.52 | -1.52 | 0.00 | 0.1911 | 0.00 | -- | -- | -- | -115.28 | -- | -123.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.46 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -75.08m | 52.15m | 14.00 | -- | 0.4331 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Cingulate Inc | 0.00 | -22.06m | 52.52m | 13.00 | -- | 11.74 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 52.53m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 52.82m | 2.00 | -- | -- | -- | 218.28 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 56.55m | 146.00 | -- | 0.3927 | -- | 6.71 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Grace Therapeutics, Inc | 0.00 | -7.82m | 56.79m | 32.00 | -- | 0.8254 | -- | -- | -0.5851 | -0.5851 | 0.00 | 4.45 | 0.00 | -- | -- | -- | -11.85 | -24.13 | -12.22 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Cingulate Inc's reporting currency: US Dollar USD
5.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 114.30k | 1.69% |
| Kestra Advisory Services LLCas of 30 Sep 2025 | 94.02k | 1.39% |
| Geode Capital Management LLCas of 30 Sep 2025 | 42.41k | 0.63% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 37.14k | 0.55% |
| UBS Securities LLCas of 31 Dec 2025 | 27.68k | 0.41% |
| LPL Financial LLCas of 30 Sep 2025 | 20.25k | 0.30% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 13.38k | 0.20% |
| Virtu Americas LLCas of 30 Sep 2025 | 10.77k | 0.16% |
| Quantum Private Wealth LLCas of 31 Dec 2025 | 10.00k | 0.15% |
| Soltis Investment Advisors LLCas of 31 Dec 2025 | 10.00k | 0.15% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
